PMID- 25433477
OWN - NLM
STAT- MEDLINE
DCOM- 20150729
LR  - 20201005
IS  - 1735-546X (Electronic)
IS  - 1735-1308 (Linking)
VI  - 11
IP  - 6
DP  - 2014 Nov 30
TI  - The utility of fluorescence in situ hybridization for diagnosis and surveillance 
      of bladder urothelial carcinoma.
PG  - 1974-9
AB  - PURPOSE: To evaluate the clinical value of fluorescence in situ hybridization 
      (FISH) for diagnosis and surveillance of bladder urothelial carcinoma (BUC). 
      MATERIALS AND METHODS: Between November 2010 and December 2013, patients 
      suspected of having BUC were examined using urine cytology and FISH assay. Based 
      on histopathological examination results, FISH results were com-pared with urine 
      cytology. In addition, patients with a history of non-muscle invasive BUC were 
      also examined using urine cytology and FISH assay at the first time of visit and 
      then monitored with cystoscopy during follow-up period. RESULTS: A total of 162 
      patients included in this study and 12 patients were excluded due to 
      uninformative FISH assays. The remaining 150 patients consisted of 108 patients 
      suspected for BUC and 42 patients with a history of non-muscle invasive BUC. The 
      sensitivities of FISH analysis and urine cytology were 72.8% and 27.2%, 
      respectively, and the difference was statistically significant (P <.05). 
      Difference between specificity of urine cytology (100%) and FISH assay (85%) was 
      not statistically significant (P >.05). At the first visit, of 42 patients, one 
      patient had positive cystoscopy, and FISH assay was positive in 26 of 41 patients 
      with negative cystoscopy. During the follow-up period (mean, 29.5 months), 18 of 
      26 patients developed recurrence, and recurrence occurred in only one of 15 
      patients with negative FISH analysis. CONCLUSION: Our results suggest that FISH 
      analysis can be used as a non-invasive diagnostic tool for patients suspect-ed of 
      having new BUC. In addition, FISH analysis may provide important prognostic 
      information to better define the individual risk for BUC recurrence.& nbsp;
FAU - Huang, Jian Wen
AU  - Huang JW
AD  - Department of Urology, Shanghai Jiao Tong University, Affiliated Sixth People's 
      Hospital, Shanghai, China.
FAU - Mu, Jia Gui
AU  - Mu JG
AD  - Department of Urology, Harbin Medical University, Affiliated First Hospital, 
      Harbin, China.
FAU - Li, Yun Wei
AU  - Li YW
AD  - Department of Urology, Harbin Medical University, Affiliated First Hospital, 
      Harbin, China.
FAU - Gan, Xiu Guo
AU  - Gan XG
AD  - Department of Urology, Harbin Medical University, Affiliated First Hospital, 
      Harbin, China.
FAU - Song, Lu Jie
AU  - Song LJ
AD  - Department of Urology, Shanghai Jiao Tong University, Affiliated Sixth People's 
      Hospital, Shanghai, China.
FAU - Gu, Bao Jun
AU  - Gu BJ
AD  - Department of Urology, Shanghai Jiao Tong University, Affiliated Sixth People's 
      Hospital, Shanghai, China.
FAU - Fu, Qiang
AU  - Fu Q
AD  - Department of Urology, Shanghai Jiao Tong University, Affiliated Sixth People's 
      Hospital, Shanghai, China.
FAU - Xu, Yue Min
AU  - Xu YM
AD  - Department of Urology, Shanghai Jiao Tong University, Affiliated Sixth People's 
      Hospital, Shanghai, China.
FAU - An, Rui Hua
AU  - An RH
AD  - Department of Urology, Harbin Medical University, Affiliated First Hospital, 
      Harbin, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20141130
PL  - Iran
TA  - Urol J
JT  - Urology journal
JID - 101286676
SB  - IM
MH  - Adult
MH  - Aged
MH  - *Carcinoma in Situ/diagnosis/pathology
MH  - *Carcinoma, Transitional Cell/diagnosis/pathology
MH  - China
MH  - Cystoscopy
MH  - Epithelial Cells/pathology
MH  - Female
MH  - Humans
MH  - In Situ Hybridization, Fluorescence/*methods
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Invasiveness
MH  - Neoplasm Recurrence, Local/*diagnosis
MH  - Predictive Value of Tests
MH  - Prognosis
MH  - Reproducibility of Results
MH  - Risk Assessment/methods
MH  - Sensitivity and Specificity
MH  - Urinary Bladder/pathology
MH  - *Urinary Bladder Neoplasms/diagnosis/pathology
EDAT- 2014/12/01 06:00
MHDA- 2015/07/30 06:00
CRDT- 2014/12/01 06:00
PHST- 2014/05/31 00:00 [received]
PHST- 2014/10/21 00:00 [accepted]
PHST- 2014/09/21 00:00 [revised]
PHST- 2014/12/01 06:00 [entrez]
PHST- 2014/12/01 06:00 [pubmed]
PHST- 2015/07/30 06:00 [medline]
AID - 2607 [pii]
PST - epublish
SO  - Urol J. 2014 Nov 30;11(6):1974-9.